RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arch Therapeutics Stock

Arch Therapeutics Net Income 2024

Arch Therapeutics Net Income

112.18 M USD

Ticker

ARTH

ISIN

US03939W1099

WKN

A1W2JT

In 2024, Arch Therapeutics's profit amounted to 112.18 M USD, a -1,706.49% increase from the -6.98 M USD profit recorded in the previous year.

The Arch Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2026e68.52
2025e47.05
2024e112.18
2023-6.98
2022-5.28
2021-6.24
2020-4.69
2019-4.55
2018-4.81
2017-7.79
2016-5.99
2015-2.95
2014-8.14
2013-1.85
2012-0.58
2011-0.01

Arch Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Arch Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Arch Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Arch Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Arch Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Arch Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Arch Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Arch Therapeutics’s growth potential.

Arch Therapeutics Revenue, EBIT and net profit per share

DateArch Therapeutics RevenueArch Therapeutics EBITArch Therapeutics Net Income
2026e335.46 M undefined294.91 M undefined68.52 M undefined
2025e226.39 M undefined197.2 M undefined47.05 M undefined
2024e140.76 M undefined120.43 M undefined112.18 M undefined
202375,720 undefined-5.04 M undefined-6.98 M undefined
202220,000 undefined-5.71 M undefined-5.28 M undefined
202110,000 undefined-6.38 M undefined-6.24 M undefined
20200 undefined-5.35 M undefined-4.69 M undefined
20190 undefined-6.37 M undefined-4.55 M undefined
20180 undefined-7.45 M undefined-4.81 M undefined
20170 undefined-7.3 M undefined-7.79 M undefined
20160 undefined-6.05 M undefined-5.99 M undefined
20150 undefined-5.46 M undefined-2.95 M undefined
20140 undefined-4.61 M undefined-8.14 M undefined
20130 undefined-1.74 M undefined-1.85 M undefined
20120 undefined-420,000 undefined-580,000 undefined
20110 undefined-10,000 undefined-10,000 undefined

Arch Therapeutics stock margins

The Arch Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Arch Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Arch Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Arch Therapeutics's sales revenue. A higher gross margin percentage indicates that the Arch Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Arch Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Arch Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Arch Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Arch Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Arch Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Arch Therapeutics Margin History

Arch Therapeutics Gross marginArch Therapeutics Profit marginArch Therapeutics EBIT marginArch Therapeutics Profit margin
2026e-3.22 %87.91 %20.43 %
2025e-3.22 %87.11 %20.78 %
2024e-3.22 %85.56 %79.69 %
2023-3.22 %-6,662.03 %-9,221.92 %
2022-200 %-28,550 %-26,400 %
2021-100 %-63,800 %-62,400 %
2020-3.22 %0 %0 %
2019-3.22 %0 %0 %
2018-3.22 %0 %0 %
2017-3.22 %0 %0 %
2016-3.22 %0 %0 %
2015-3.22 %0 %0 %
2014-3.22 %0 %0 %
2013-3.22 %0 %0 %
2012-3.22 %0 %0 %
2011-3.22 %0 %0 %

Arch Therapeutics Aktienanalyse

What does Arch Therapeutics do?

Arch Therapeutics Inc. is a Massachusetts-based company specializing in the development of medical devices. The company was founded in 2006 and has expanded its activities to manufacturing innovative medical products that can be used in various surgical procedures. The business model of Arch Therapeutics is based on the development of medical devices that aim to enable faster recovery for patients. The company utilizes a patented technology platform called "AC5" for the manufacturing and marketing of devices for various medical applications. The company has various divisions specializing in different medical applications. One main focus is the development of devices for hemostasis (blood clotting) in surgery, which is currently in the testing phase. Arch Therapeutics aims to provide a better alternative to existing solutions such as surgical clips or sutures, which are often associated with undesirable side effects. Another focus of Arch Therapeutics is the manufacturing of devices for dermatology. The company has developed a technology that enables a new and unique process for the rapid healing of wounds. This process is especially relevant for the treatment of difficult-to-heal wounds and chronic wounds. The company also has a division for ophthalmic surgery, which has developed a patented device technology for the treatment of glaucoma-related issues. This technology is intended to be a better alternative to conventional treatment methods such as eye drops. Arch Therapeutics' portfolio includes a wide range of medical devices and solutions for various medical applications. These products are designed to enable better patient recovery and have been developed by a group of experts, ensuring high quality and effectiveness. The offered products also include dermatology products, adhesion barriers, surgical J-clips, as well as wound closure and hemostasis devices. Overall, Arch Therapeutics has a strong potential for growth and expansion in the medical device industry. The company has already obtained patents for its AC5 platform and developed a wide range of products for various medical applications. With a dedicated team of employees, the company has laid a strong foundation for its future and is expected to remain a leading provider of medical devices in the coming years. Arch Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Arch Therapeutics's Profit Margins

The profit margins of Arch Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Arch Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Arch Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Arch Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Arch Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Arch Therapeutics stock

How much profit has Arch Therapeutics made this year?

Arch Therapeutics has made 112.18 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -1,706.49% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Arch Therapeutics publish its earnings?

Arch Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Arch Therapeutics?

The profits of Arch Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Arch Therapeutics?

You can learn more about the earnings of Arch Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Arch Therapeutics pay?

Over the past 12 months, Arch Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arch Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Arch Therapeutics?

The current dividend yield of Arch Therapeutics is .

When does Arch Therapeutics pay dividends?

Arch Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arch Therapeutics?

Arch Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Arch Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arch Therapeutics located?

Arch Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arch Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arch Therapeutics from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Arch Therapeutics pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Arch Therapeutics in the year 2023?

In the year 2023, Arch Therapeutics distributed 0 USD as dividends.

In which currency does Arch Therapeutics pay out the dividend?

The dividends of Arch Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Arch Therapeutics

Our stock analysis for Arch Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arch Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.